Eckhard Brueggemann - STADA Arzneimittel Insider

STDAF -- USA Stock  

USD 94.05  0.000003  0.00%

Member of the Supervisory Board

Dr. Eckhard Brueggemann was Member of the Supervisory Board of STADA Arzneimittel AG from August 24 2009 August 26 2016. From February 5 2001 to August 24 2009 he occupied the position of Chairman of the Supervisory Board at the Company. Before that he served as Member of the Supervisory Board at STADA Arzneimittel AG from 1997. He started a medical practice in Herne Germany in 1972. From 1983 to 1993 he was Chairman of the German Association of General Practitioners. Since 1993 he was a Board Member of the Federal Association of German Family Doctors. In 1997 he was elected to the Supervisory Board of STADA Arzneimittel AG. He completed his medical studies in Marburg and Essen Germany and Innsbruck Austria and is a specialist in general medicine.
Age: 75  Executive Since 2009  Ph.D    
49 6101 603 0

Management Efficiency

The company has return on total asset (ROA) of 5.45 % which means that it generated profit of $5.45 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 9.23 % meaning that it generated $9.23 on every $100 dollars invested by stockholders.
The company has accumulated 1.62 B in total debt with debt to equity ratio (D/E) of 130.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. STADA Arzneimittel Aktiengesellschaft has Current Ratio of 0.64 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Similar Executives

Entity Summary

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH. STADA Arzneimittel operates under Drug Manufacturers - Specialty Generic classification in USA and traded on OTC Market. It employs 10176 people.STADA Arzneimittel Aktiengesellschaft (STDAF) is traded on OTC Market in USA. It is located in Stadastrasse 2-18 and employs 10,176 people.

STADA Arzneimittel A Leadership Team

Carl Oetker, Executive
JanNicolas Garbe, Executive
Dieter Koch, Executive
Eckhard Brueggemann, Executive, Ph.D
Mark Keatley, CFO
Ralph Grobecker, Managing Director, Ph.D
Martin Abend, Chairman, Ph.D
Matthias Wiedenfels, Executive, Ph.D
Arnold Hertzsch, Executive, Ph.D
Halil Duru, Executive
Tina Mueller, Executive
Engelbert Willink, Chairman
Barthold Piening, Executive, Ph.D
Helmut Kraft, CFO
Ute Pantke, Executive, Ph.D
Carsten Cron, Executive
Hartmut Retzlaff, Chairman
Bernhard Duettmann, CFO
Miguel Pagan, Executive
Claudio Albrecht, Chairman, Ph.D
Michael Siefke, Executive
Leslie Iltgen, President
Eric Cornut, Executive
Robert Knerr, Executive
Jens Steegers, Executive
Birgit Kudlek, Executive, Ph.D
Guenter Au, Chairman, Ph.D
Constantin Meyer, Executive
Rolf Hoffmann, Executive, MBA
Markus Metzger, Director
Benjamin Kunstler, Executive
Gunnar Riemann, Executive, Ph.D
Bruno Schick, Executive

Stock Performance Indicators

Current Sentiment - STDAF

STADA Arzneimittel A Investor Sentiment
Macroaxis portfolio users are evenly split in their outlook on investing in STADA Arzneimittel Aktiengesellschaft. What is your outlook on investing in STADA Arzneimittel Aktiengesellschaft? Are you bullish or bearish?
50% Bullish
50% Bearish

Trending Equities

Currently Active Assets on Macroaxis
Purchased over 100 shares of
few days ago
Traded for 10.44
Purchased over 300 shares of
few days ago
Traded for 6.24
Purchased over 70 shares of
few days ago
Traded for 23.42
Purchased over 200 shares of
few days ago
Traded for 8.1
Purchased over 400 shares of
few days ago
Traded for 4.74
Also please take a look at World Market Map. Please also try Portfolio Quick Import module to import or update all your transactions via one easy-to-use interface.